InvestorQ : What were the major highlights of the quarterly results of Ajanta Pharma for the March 2022 quarter?
Dia Deshpande made post

What were the major highlights of the quarterly results of Ajanta Pharma for the March 2022 quarter?

Answer
image
swati Bakhda answered.
3 days ago
Follow

Home bred pharmaceutical company, Ajanta Pharma, saw sales grow by 15% for the Q4FY22 quarter at Rs870.29 crore. FY22 full year sales revenues were up 15.6% at Rs3,341 crore. Ajanta Pharma reported 13% higher India sales at Rs245 crore. In the fourth quarter, Ajanta Pharm witnessed growth across various business verticals. It grew by 11% in cardiology vertical, 25% in ophthalmology vertical, 17% in dermatology and 28% in pain management vertical. Pain management was the big growth story for the quarter.

Ajanta Pharma

Rs in Crore

Mar-22

Mar-21

YOY

Dec-21

QOQ

Total Income (Rs cr)

₹ 870.29

₹ 756.84

14.99%

₹ 837.91

3.86%

Net Profit (Rs cr)

₹ 151.21

₹ 159.26

-5.05%

₹ 191.78

-21.15%

Diluted EPS (Rs)

₹ 17.70

₹ 18.40

₹ 22.16

Net Margins

17.37%

21.04%

22.89%

  

The company did take a hit on the profitability front. Net profits for Q4FY22 fell -5.05% to Rs151.21 crore. This pressure was largely on the back of a spike raw material costs and manpower costs. Ajanta Pharma also reported a fall in EBITDA from Rs259 crore to Rs207 crore yoy, even as the EBITDA margins tapered to 24% in the quarter. Net margins stood at a level of 17.37% for the Q4FY22 compared to 21.04% in Q4FY21. Net profit margins or NPM were also lower sequentially as compared to 22.89% in Q3FY22.

3 Views